EUCTR2010-019428-30-GB进行中（未招募）不适用
A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIIb tudy to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Metformin and Sulfonylurea in Subjects with Type 2 Diabetes who have Inadequate Glycaemic control with the Combination of Metformin and Sulfonylurea
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 275
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provision of written informed consent prior to the performance of any study-related procedures.
- •2.Males and females who are =18 years of age at the time of obtaining consent at Visit 1.
- •3.Clinical diagnosis of type 2 diabetes with uncontrolled glycaemia in spite of being on the combination of metformin IR or XR (MTD, minimum dose for enrolment being 1500 mg) plus sulfonylurea (at MTD, with minimum dose for enrolment being =50% of the maximum recommended dose) daily, for at least 8 weeks prior to Visit 1.
- •4. HbA1c =7% and =10% obtained at Visit 1 as confirmed by the central laboratory.
- •5.BMI =40 kg/m2.
- •6.Females of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the study in such a manner that the risk of pregnancy is minimised and have a negative urine preganancy test at Visit 2 and each scheduled study visit thereafter.
- •Definitions: - Females of Child Bearing Potential - women who have experienced menarche but who have not been permanently or surgically sterilised, are not postmenopausal and are capable of procreation. - Females NOT of Child Bearing Potential - women who have undergone successful surgical sterilisation (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or who are postmenopausal. - Postmenopausal Women - women will be considered postmenopausal if they have had amenorrhea > or = 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level >35 mIU/ml.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Any clinically significant abnormality identified on physical examination or laboratory tests that would compromise patient’s safety or successful participation in the study as judged by the investigator.
- •2.Pregnant or breastfeeding females.
- •3.Symptoms of poorly controlled diabetes including but not limited to marked polyuria and polydipsia with more than 10% weight loss in the 3 months before Visit 1 or other signs and symptoms.
- •4.History of diabetic ketoacidosis or hyperosmolar non-ketotic coma.
- •5.Current or prior use within 3 months of Visit 1, of insulin, DPP4 inhibitor, GLP-1 analogues (exenatide or liraglutide), and/or other oral anti-diabetic agents (other than metformin and sulfonylurea).
- •6.Estimated CrCl <60 ml/min at Visit 2.
- •7.Congestive heart failure defined as New York Heart association (NYHA) class III or IV (see Appendix D) and/or left ventricular ejection fraction of <40%.
- •8.Active liver disease and/or significant abnormal liver function define as aspartate aminotransferase (AST) >3 x the upper limit of normal (ULN) and/or alanine aminotransferase (ALT) >3 x ULN and/or bilirubin >2.0 mg/dL (> 34 µmol) at Visit 2.
- •9.Creatine kinase =10 x ULN at Visit 2.
- •10.Treatment with systemic glucocorticoids other than replacement therapy. Inhaled, local injected and topical use of glucocorticoids is allowed.
- •11.Treatment with CYP3A4 inducers, such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin and St. John’s Wort, and/or potent CYP3A4/5 inhibitors, such as delavirdine, indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole (topical use is allowed), nefazodone, saquinavir and telithromycin.
- •12.Patients who could have a potential allergy to the investigational product or any of its formulation excipients.
- •13.Contraindications to therapy as outlined in the metformin and/or sulfonylurea package insert including conditions leading to an increased risk of hypoxemia and lactic acidosis.
- •14.History of haemoglobinopathies (sickle cell anaemia or thalassemias, sideroblastic anaemia).
- •15.History of alcohol abuse or illegal drug abuse within the past 12 months prior to Visit 1.
- •16.Involvement in the planning and conduct of the study (applies to both AstraZeneca and Bristol-Myers Squibb personnel or personnel at the study centre).
- •17.Participation in an interventional clinical study during the 30 days prior to Visit 1.
- •18.Donation of blood, plasma or platelets within the 3 months prior to Visit 1.
- •19.Individuals, in the opinion of the investigator, whose participation in this
- •study may pose a significant risk to the patient and could render the patient unable to successfully complete the study.
- •20.Suspected or confirmed poor protocol or medication compliance as judged by the investigator.
- •21.Previous enrolment or randomisation in the present study.
研究者
相似试验
进行中（未招募）
不适用
A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, International Phase III Study with a 24-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg Daily in Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on a DPP-4 inhibitor (Sitagliptin) Alone or in Combination with MetformiType 2 Diabetes MellitusEUCTR2009-012806-37-PLAstraZeneca AB810
进行中（未招募）
1 期
A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, International Phase III Study with a 24-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg Daily in Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on a DPP-4 inhibitor (Sitagliptin) Alone or in Combination with MetformiMedDRA version: 12.0 Level: LLT Classification code 10012613 Term: Diabetes mellitus non-insulin-dependentType 2 Diabetes MellitusEUCTR2009-012806-37-GBAstraZeneca AB810
已完成
3 期
A study to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Metformin and Sulfonylurea in Subjects with Type 2 DiabetesCTRI/2010/091/001110AstraZeneca Singapore Pte Ltd69
进行中（未招募）
不适用
Evaluation of Safety and Efficacy of Dapagliflozin in subjects with Type 2 Diabetes who have Inadequate Glycaemic Control on background combination of Metformin and SulfonylureaType II diabetes mellitusMedDRA version: 14.0Level: LLTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-002231-26-SKAstraZeneca AB216
进行中（未招募）
1 期
Evaluation of Safety and Efficacy of Dapagliflozin in subjects with Type 2 Diabetes who have Inadequate Glycaemic Control on background combination of Metformin and SulfonylureaType II diabetes mellitusMedDRA version: 14.0Level: LLTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-002231-26-ESAstraZeneca AB218